Mengis Capital Management Inc. lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 29,645 shares of the company’s stock after selling 50 shares during the period. Johnson & Johnson comprises about 2.8% of Mengis Capital Management Inc.’s holdings, making the stock its 7th biggest position. Mengis Capital Management Inc.’s holdings in Johnson & Johnson were worth $3,921,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. OLD Point Trust & Financial Services N A boosted its position in Johnson & Johnson by 2.2% during the second quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after purchasing an additional 1,321 shares during the period. Lynch & Associates IN boosted its position in Johnson & Johnson by 0.9% during the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after purchasing an additional 841 shares during the period. Welch & Forbes LLC boosted its position in shares of Johnson & Johnson by 0.9% in the second quarter. Welch & Forbes LLC now owns 718,331 shares of the company’s stock valued at $95,028,000 after acquiring an additional 6,730 shares during the period. Oakbrook Investments LLC boosted its position in shares of Johnson & Johnson by 7.4% in the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after acquiring an additional 9,375 shares during the period. Finally, Janney Montgomery Scott LLC boosted its position in shares of Johnson & Johnson by 0.5% in the second quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock valued at $102,110,000 after acquiring an additional 3,533 shares during the period. Hedge funds and other institutional investors own 65.61% of the company’s stock.

A number of research firms have recently commented on JNJ. Citigroup Inc. raised their price objective on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Vetr upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective for the company in a research report on Monday, October 30th. Leerink Swann restated an “outperform” rating and issued a $165.00 price objective (up from $150.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the company an “outperform” rating in a research report on Wednesday, October 18th. Finally, Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research report on Wednesday, October 18th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus target price of $143.70.

Johnson & Johnson (NYSE JNJ) opened at $137.93 on Tuesday. The company has a market cap of $370,550.00, a P/E ratio of 19.33, a price-to-earnings-growth ratio of 2.80 and a beta of 0.82. Johnson & Johnson has a one year low of $109.32 and a one year high of $144.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $1.68 earnings per share. sell-side analysts predict that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 2.44%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

WARNING: This story was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/21/mengis-capital-management-inc-sells-50-shares-of-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.